<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589901</url>
  </required_header>
  <id_info>
    <org_study_id>200507CX</org_study_id>
    <nct_id>NCT00589901</nct_id>
  </id_info>
  <brief_title>An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)</brief_title>
  <official_title>Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the time to progression. Secondary
      objectives are safety, OS and pharmacogenetic analysis. Sixty patients will be enrolled into
      this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Xeloda (capecitabine) is converted to 5-fluorouracil by thymidine phosphorylase, and
      cyclophosphamide is capable of upregulating the expression of thymidine phosphorylase
      suggesting a synergistic effect.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TTP (first treatment of this regimen to disease progression)</measure>
    <time_frame>every two cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>all cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacogenetic analysis</measure>
    <time_frame>collect blood samples before this therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>phase II trial of capecitabine and cyclophosphamide in the management of metastatic breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine and cyclophosphamide</intervention_name>
    <description>capecitabine 1000 mg/m2 oral Bid d1-14
cyclophosphamide 65 mg/m2 oral Qd d1-14</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed breast cancer

          -  Anthracycline and taxane pretreated metastatic breast cancer

          -  Have not been previously treated with capecitabine

          -  ECOG performance status of ≤ 1

          -  Are female and ≥ 18 and ≤ 70 years of age

          -  Have at least one target lesion according to the RECIST criteria

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  ECOG ≥ 2

          -  Have been treated with capecitabine

          -  Evidence of CNS metastasis

          -  History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast
             cancer

          -  Abnormal laboratory values: hemoglobin &lt; 8.0 g/dl, neutrophils &lt; 1.5×10^9/L, platelets
             &lt; 100×10^9/L, serum creatinine &gt; upper limit of normal (ULN), serum bilirubin &gt; ULN,
             ALT and AST &gt; 5×ULN, AKP &gt; 5×ULN

          -  Serious uncontrolled intercurrent infection

          -  Life expectancy of less than 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhonghua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhonghua Wang, MD</last_name>
    <phone>8613918322628</phone>
    <email>zhonghuawang95@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>+86200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Xichun Hu, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fumoleau P, Largillier R, Clippe C, Dièras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Curé H, Vuillemin E, Morère JF, Montestruc F, Mouri Z, Namer M. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42.</citation>
    <PMID>14962720</PMID>
  </reference>
  <reference>
    <citation>Endo M, Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer. 1999 Sep 24;83(1):127-34.</citation>
    <PMID>10449619</PMID>
  </reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>April 17, 2008</last_update_submitted>
  <last_update_submitted_qc>April 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Base of drug clinical trials, Fudan University Cancer Hospital</name_title>
    <organization>Fudan University Cancer Hospital</organization>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>capecitabine</keyword>
  <keyword>synergistic effect</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 11, 2010</submitted>
    <returned>February 26, 2010</returned>
    <submitted>May 25, 2010</submitted>
    <returned>June 18, 2010</returned>
    <submitted>July 9, 2010</submitted>
    <returned>August 9, 2010</returned>
    <submitted>March 16, 2011</submitted>
    <returned>April 15, 2011</returned>
    <submitted>July 1, 2011</submitted>
    <returned>July 29, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

